Solifenacin

Solifenacin (YM905) is a competitive muscarinic receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle.

Synonyms:

(1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;

(1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate;

[(8R)-1-azabicyclo[2.2.2]octan-8-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;

Properties:

Density: 1.24g/cm3
Boiling Point: 505.5ºC at 760 mmHg
Flash Point: 259.5ºC
Refractive Index: 1.648
Vapor Pressure: 2.41E-10mmHg at 25°C

AChR Inhibitors Related Products:

Donepezil Hcl; (-)-Huperzine A; PNU-120596; Scopolamine hydrobromide; Rivastigmine Tartrate; Darifenacin hydrobromide; Vinblastine sulfate; Tolterodine tartrate; Amfebutamone hydrochloride; Solifenacin succinate; Trospium chloride; Pyridostigmine bromide; Varenicline; Revefenacin; Imidafenacin

[1]. Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):97-103.

[2]. Suzuki M, et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarctedrats. Eur J Pharmacol. 2005 Apr 4;512(1):61-6.